Literature DB >> 30957953

Anti-fibrotic mechanisms of angiotensin AT2 -receptor stimulation.

Colin Sumners1, Antonio Augusto Peluso2, Andreas Houe Haugaard2, Jesper Bork Bertelsen2, Ulrike Muscha Steckelings2.   

Abstract

The angiotensin AT2 -receptor is a main receptor of the protective arm of the renin-angiotensin system. Understanding of this unconventional G-protein coupled receptor has significantly advanced during the past decade, largely because of the availability of a selective non-peptide AT2 -receptor agonist, which allowed the conduct of a multitude of studies in animal disease models. This article reviews such preclinical studies that in their entirety provide strong evidence for an anti-fibrotic effect mediated by activation of the AT2 -receptor. Prevention of the development of fibrosis by AT2 -receptor stimulation has been demonstrated in lungs, heart, blood vessels, kidney, pancreas and skin. In lungs, AT2 -receptor stimulation was even able to reverse existing fibrosis. The article further discusses intracellular signalling mechanisms mediating the AT2 -receptor-coupled anti-fibrotic effect, including activation of phosphatases and subsequent interference with pro-fibrotic signalling pathways, induction of matrix-metalloproteinases and hetero-dimerization with the AT1 -receptor, the TGF-βRII-receptor or the RXFP1-receptor for relaxin. Knowledge of the anti-fibrotic effects of the AT2 -receptor is of particular relevance because drugs targeting this receptor have entered clinical development for indications involving fibrotic diseases.
© 2019 Scandinavian Physiological Society. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  angiotensin; angiotensin AT2-receptor; fibrosis; fibrotic disease

Year:  2019        PMID: 30957953     DOI: 10.1111/apha.13280

Source DB:  PubMed          Journal:  Acta Physiol (Oxf)        ISSN: 1748-1708            Impact factor:   6.311


  10 in total

1.  Angiotensin receptor expression revealed by reporter mice and beneficial effects of AT2R agonist in retinal cells.

Authors:  Amrisha Verma; Ping Zhu; Annette de Kloet; Eric Krause; Colin Sumners; Qiuhong Li
Journal:  Exp Eye Res       Date:  2019-08-23       Impact factor: 3.467

Review 2.  The Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target.

Authors:  U Muscha Steckelings; Robert E Widdop; Edward D Sturrock; Lizelle Lubbe; Tahir Hussain; Elena Kaschina; Thomas Unger; Anders Hallberg; Robert M Carey; Colin Sumners
Journal:  Pharmacol Rev       Date:  2022-10       Impact factor: 18.923

Review 3.  Brain angiotensin converting enzyme-2 in central cardiovascular regulation.

Authors:  Mazher Mohammed; Clara Berdasco; Eric Lazartigues
Journal:  Clin Sci (Lond)       Date:  2020-10-16       Impact factor: 6.124

Review 4.  Novel therapeutics for the treatment of hypertension and its associated complications: peptide- and nonpeptide-based strategies.

Authors:  Trupti Ghatage; Srashti Gopal Goyal; Arti Dhar; Audesh Bhat
Journal:  Hypertens Res       Date:  2021-03-17       Impact factor: 5.528

5.  Strengthening CoViD-19 therapy via combinations of RAS modulators.

Authors:  Veselina V Uzunova; Angel Todev; Jacqueline Zarkos; Daniel Addai; Julian Ananiev; Pavel Rashev; Radostina Alexandrova; Anna Tolekova
Journal:  Med Hypotheses       Date:  2021-03-25       Impact factor: 1.538

6.  Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial.

Authors:  Göran Tornling; Rohit Batta; Joanna C Porter; Bryan Williams; Thomas Bengtsson; Kartikeya Parmar; Reema Kashiva; Anders Hallberg; Anne Katrine Cohrt; Kate Westergaard; Carl-Johan Dalsgaard; Johan Raud
Journal:  EClinicalMedicine       Date:  2021-10-24

7.  Multifunctional biomaterial platforms for blocking the fibrosis process and promoting cellular restoring effects in myocardial fibrosis therapy.

Authors:  Tian Yue; Shiqiang Xiong; Dezhi Zheng; Yi Wang; Pan Long; Jiali Yang; Dunzhu Danzeng; Han Gao; Xudong Wen; Xin Li; Jun Hou
Journal:  Front Bioeng Biotechnol       Date:  2022-09-15

Review 8.  The Impact of the Renin-Angiotensin-Aldosterone System on Inflammation, Coagulation, and Atherothrombotic Complications, and to Aggravated COVID-19.

Authors:  M Ekholm; T Kahan
Journal:  Front Pharmacol       Date:  2021-06-17       Impact factor: 5.810

9.  Angiotensin Type 2 and Mas Receptor Activation Prevents Myocardial Fibrosis and Hypertrophy through the Reduction of Inflammatory Cell Infiltration and Local Sympathetic Activity in Angiotensin II-Dependent Hypertension.

Authors:  Giovanna Castoldi; Raffaella Carletti; Silvia Ippolito; Andrea Stella; Gianpaolo Zerbini; Sara Pelucchi; Giovanni Zatti; Cira R T di Gioia
Journal:  Int J Mol Sci       Date:  2021-12-20       Impact factor: 5.923

Review 10.  Advances in the Treatment Strategies in Hypertension: Present and Future.

Authors:  Paolo Verdecchia; Claudio Cavallini; Fabio Angeli
Journal:  J Cardiovasc Dev Dis       Date:  2022-03-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.